Diabetes and obesity, for example, are chronic diseases with potential lifelong health consequences
With a growing number of patients using these medications for diabetes or to meet certain optimization goals before undergoing hip and knee reconstructive surgery, our aim was to establish evidence-based guidelines on when to discontinue these to enhance patient safety and surgical success. The study, Optimal Timing for Cessation of GLP-1 Agonist Before Elective Total Hip and Knee Arthroplasty, obtained data from the TriNetX Research Network, a multi-institutional national aggregated database, to identify patients who underwent TKA or THA from January 1, 2018 to January 1, 2023
Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions
Safety is ensured through comprehensive initial screening and ongoing monitoring